KR20110015699A - 디아자카르바졸 및 사용 방법 - Google Patents

디아자카르바졸 및 사용 방법 Download PDF

Info

Publication number
KR20110015699A
KR20110015699A KR1020117000608A KR20117000608A KR20110015699A KR 20110015699 A KR20110015699 A KR 20110015699A KR 1020117000608 A KR1020117000608 A KR 1020117000608A KR 20117000608 A KR20117000608 A KR 20117000608A KR 20110015699 A KR20110015699 A KR 20110015699A
Authority
KR
South Korea
Prior art keywords
alkyl
groups
compound
heterocyclyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020117000608A
Other languages
English (en)
Korean (ko)
Inventor
헤이젤 존 다이크
엠마누엘라 간치아
루이스 제이. 가자드
사이먼 찰스 굿에이커
조세프 피. 라이시카토스
칼럼 맥레오드
카렌 윌리엄스
후이펜 첸
Original Assignee
제넨테크, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제넨테크, 인크. filed Critical 제넨테크, 인크.
Publication of KR20110015699A publication Critical patent/KR20110015699A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020117000608A 2008-06-11 2009-06-10 디아자카르바졸 및 사용 방법 Withdrawn KR20110015699A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US6075008P 2008-06-11 2008-06-11
US61/060,750 2008-06-11
US14800409P 2009-01-28 2009-01-28
US61/148,004 2009-01-28

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020167015993A Division KR101764556B1 (ko) 2008-06-11 2009-06-10 디아자카르바졸 및 사용 방법

Publications (1)

Publication Number Publication Date
KR20110015699A true KR20110015699A (ko) 2011-02-16

Family

ID=41066268

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020117000608A Withdrawn KR20110015699A (ko) 2008-06-11 2009-06-10 디아자카르바졸 및 사용 방법
KR1020167015993A Expired - Fee Related KR101764556B1 (ko) 2008-06-11 2009-06-10 디아자카르바졸 및 사용 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020167015993A Expired - Fee Related KR101764556B1 (ko) 2008-06-11 2009-06-10 디아자카르바졸 및 사용 방법

Country Status (12)

Country Link
US (1) US20110124654A1 (https=)
EP (1) EP2324024B1 (https=)
JP (2) JP5677945B2 (https=)
KR (2) KR20110015699A (https=)
CN (1) CN102119162B (https=)
AU (1) AU2009258115B2 (https=)
BR (1) BRPI0909957A2 (https=)
CA (1) CA2726114A1 (https=)
ES (1) ES2392489T3 (https=)
IL (1) IL209548A (https=)
MX (1) MX2010013606A (https=)
WO (1) WO2009151589A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110015699A (ko) * 2008-06-11 2011-02-16 제넨테크, 인크. 디아자카르바졸 및 사용 방법
RU2017127088A (ru) 2010-11-16 2019-02-04 Эррэй Биофарма Инк. Комбинация ингибиторов чекпойнт-киназы 1 и ингибиторов киназы wee 1
GB201201566D0 (en) * 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds
SG11201406818VA (en) * 2012-04-23 2014-11-27 Genentech Inc Intermediates and processes for preparing compounds
WO2014116859A1 (en) * 2013-01-23 2014-07-31 The University Of Chicago Methods and compositions for inhibiting human copper trafficking proteins atox1 and ccs
CN112472699A (zh) 2013-07-26 2021-03-12 种族肿瘤学公司 改善比生群及衍生物的治疗益处的组合方法
CN105358558B (zh) 2013-10-08 2017-09-26 豪夫迈·罗氏有限公司 作为tau‑pet‑配体的二氮杂咔唑衍生物
JP6840931B2 (ja) * 2015-03-09 2021-03-10 東ソー株式会社 縮環芳香族化合物の製造方法
US20170067946A1 (en) 2015-06-08 2017-03-09 Zac WHEELER Monitoring system with low power usage
RU2019102647A (ru) 2016-07-01 2020-08-03 Г1 Терапьютикс, Инк. Антипролиферационные средства на основе пиримидина
MX375720B (es) 2016-09-09 2025-03-04 Hoffmann La Roche Proceso para preparacion de 2-(6-nitropiridin-3-il)-9h-dipirido[2,3-beta;3',4'-d]pirrol.
WO2019168874A1 (en) 2018-02-27 2019-09-06 The Research Foundation For The State University Of New York Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
KR20230012547A (ko) 2020-05-19 2023-01-26 쥐원 쎄라퓨틱스, 인크. 의학적 장애의 치료를 위한 시클린-의존성 키나제 억제 화합물
CN115572282B (zh) * 2021-07-05 2024-07-09 华东理工大学 含芳杂环结构的吡唑酰胺类化合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1054039B (zh) * 2000-03-15 2010-04-16 萨诺费－阿文蒂斯德国有限公司 取代的β-咔啉
EP1268477B1 (en) 2000-03-15 2010-04-21 Sanofi-Aventis Deutschland GmbH Substituted beta-carbolines with ikb-kinase inhibiting activity
KR100774855B1 (ko) * 2000-04-27 2007-11-08 아스텔라스세이야쿠 가부시키가이샤 축합 헤테로아릴 유도체
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
EP1599202A1 (en) * 2003-02-17 2005-11-30 Pharmacia Italia S.p.A. Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
PE20060526A1 (es) * 2004-06-15 2006-07-13 Schering Corp Compuestos triciclicos como antagonistas de mglur1
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US8618121B2 (en) 2007-07-02 2013-12-31 Cancer Research Technology Limited 9H-pyrimido[4,5-B]indoles, 9H-pyrido[4',3':4,5]pyrrolo[2,3-D]pyridines, and 9H 1,3,6,9 tetraaza-fluorenes as CHK1 kinase function inhibitors
KR20110015699A (ko) * 2008-06-11 2011-02-16 제넨테크, 인크. 디아자카르바졸 및 사용 방법

Also Published As

Publication number Publication date
EP2324024B1 (en) 2012-09-26
CA2726114A1 (en) 2009-12-17
ES2392489T3 (es) 2012-12-11
KR101764556B1 (ko) 2017-08-02
IL209548A (en) 2014-03-31
WO2009151589A1 (en) 2009-12-17
JP2011522888A (ja) 2011-08-04
AU2009258115B2 (en) 2015-01-29
IL209548A0 (en) 2011-01-31
BRPI0909957A2 (pt) 2016-04-19
AU2009258115A1 (en) 2009-12-17
KR20160074680A (ko) 2016-06-28
AU2009258115A2 (en) 2011-05-12
MX2010013606A (es) 2010-12-21
JP5677945B2 (ja) 2015-02-25
EP2324024A1 (en) 2011-05-25
JP2014196309A (ja) 2014-10-16
US20110124654A1 (en) 2011-05-26
CN102119162A (zh) 2011-07-06
CN102119162B (zh) 2014-10-08

Similar Documents

Publication Publication Date Title
KR101764556B1 (ko) 디아자카르바졸 및 사용 방법
CN105358552B (zh) 芳基喹唑啉
EP2207781B1 (en) Thiazolopyrimidine p13k inhibitor compounds and methods of use
KR101710732B1 (ko) 디아자카르바졸 및 사용 방법
JP5689069B2 (ja) ピラゾロピリジンｐｉ３ｋ阻害剤化合物及び使用方法
EP2164850B1 (en) N-substituted azaindoles and methods of use
US20110130406A1 (en) Pyrazolo-pyridines as tyrosine kinase inhibitors
CN109219604A (zh) 四氢异喹啉雌激素受体调节剂及其用途
AU2014331049A1 (en) Conformationally restricted PI3K and mTOR inhibitors
EP2300457B1 (en) Substituted pyrroles and methods of use
US20150368244A1 (en) Diazacarbazoles and methods of use
HK40091719B (zh) 取代的稠杂环化合物及其制备方法与应用
HK40091719A (zh) 取代的稠杂环化合物及其制备方法与应用
HK1210166A1 (en) Fused tricyclic amide compounds as multiple kinase inhibitors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20110110

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140605

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20151215

Patent event code: PE09021S01D

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20160615

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20161010

WITB Written withdrawal of application